Eosinophilia in primary biliary cirrhosis

Area of Science:

• Hepatology
• Immunology
• Hematology

Background:

• Eosinophilia has been observed in patients with primary biliary cirrhosis (PBC).
• The distinctiveness of eosinophilia as a feature of PBC requires further investigation.
• Understanding eosinophil dynamics in PBC is crucial for diagnosis and treatment.

Purpose of the Study:

• To determine if eosinophilia is a distinctive characteristic of PBC.
• To investigate the relationship between eosinophil levels and clinical aspects of PBC.
• To assess the impact of ursodeoxycholic acid (UDCA) treatment on eosinophilia in PBC.

Main Methods:

• Utilized a flow cytometry-based hematology analyzer (Technicon H6000) for leukocyte differential analysis.
• Compared peripheral blood eosinophil counts in 38 PBC patients versus 131 patients with other liver diseases.
• Quantified eosinophils in 19 PBC patients before and after 4 weeks of UDCA treatment.

Main Results:

• PBC patients exhibited significantly higher relative and absolute eosinophil counts compared to other liver disease groups.
• Eosinophilia was more pronounced in early histological stages of PBC and correlated with basophil counts, serum IgA, and portal tract eosinophil infiltration.
• UDCA treatment markedly reduced eosinophil counts in PBC patients.

Conclusions:

• Eosinophilia is a common and distinctive feature in primary biliary cirrhosis (PBC).
• Ursodeoxycholic acid (UDCA) treatment ameliorates eosinophilia and improves liver function tests in PBC patients.
• Eosinophilia may serve as an early diagnostic clue for PBC, particularly in its initial stages.